Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital

"Risk of de novo or secondary cancer after solid organ or allogeneic haematopoietic stem cell transplantation"

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. ABO blood types and sepsis mortality

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

PURPOSE: Solid organ (SOT) and allogeneic haematopoietic stem cell (HSCT) transplant recipients have elevated risks of de novo or secondary cancer. We explored risk factors hereof.

METHODS: Among SOT and HSCT between January 2004 and December 2014, standardised incidence ratio (SIR) of de novo/secondary cancer compared with the Danish population was determined and risk factors were identified using Poisson regression.

RESULTS: During a median of 3.4 (IQR 1.3-6.4) and 2.6 (0.8-5.4) person-years (PY) after SOT and HSCT, a total of 212/1656 (13%) and 75/992 (8%) persons developed cancer; SIR 3.61 (3.0-4.3) and 2.2 (1.6-3.0), resp.). SIR correlated with younger age and was highest for skin and haematological cancers for both types of transplantation. Within the cohort, cancer was associated with older age (adjusted incidence rate ratio > 50 vs ≤ 19 years, among SOT and HSCT: 9.4 (3.4-25.7) and 25.4 (5.1-126.0), resp.) and current elevated C-reactive protein (CRP) (≥ 10 vs < 10 mg/L: 2.5 (1.8-3.4) and 2.3 (1.4-3.9), resp.), but neither with prior cancer nor type of immunosuppressants.

CONCLUSION: Rates of de novo or secondary cancers are elevated in both SOT and HSCT compared with the general population and mainly for skin and haematological cancers. Among transplant recipients, older age and current elevated CRP are risk factors.

Original languageEnglish
JournalJournal of Cancer Research and Clinical Oncology
Issue number12
Pages (from-to)3125-3135
Number of pages11
Publication statusPublished - Dec 2019

    Research areas

  • Adult, Cohort Studies, Female, Hematopoietic Stem Cell Transplantation/adverse effects, Humans, Immunosuppressive Agents/adverse effects, Incidence, Male, Middle Aged, Neoplasms, Second Primary/etiology, Neoplasms/etiology, Organ Transplantation/adverse effects, Risk Factors, Transplant Recipients, Young Adult

ID: 58076015